Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349682 | 1.00 | ESR1 (0.45) | ESR1CHRNB4CHRNA3CHRNA1CHRNG | |
| SCHEMBL13561413 | 1.00 | ESR1 (0.45) | ESR1CHRNB4CHRNA3CHRNA1CHRNG | |
| SCHEMBL25402074 | 0.84 | RBP4 (0.36) | CHRNB2CHRNA4HPGDSRBP4PROKR1 | |
| SCHEMBL29761235 | 0.84 | RBP4 (0.36) | CHRNB2CHRNA4HPGDSRBP4PROKR1 | |
| SCHEMBL25951618 | 0.83 | CHRNB2 (0.51) | ESR1CHRNB4CHRNA3CHRNA1CHRNG | |
| SCHEMBL8205378 | 0.81 | CHRNB2 (0.50) | ESR1CHRNB4CHRNA3CHRNA1CHRNG | |
| SCHEMBL14003852 | 0.81 | CHRNB2 (0.53) | ESR1CHRNB2CHRNA4HPGDESR2 | |
| SCHEMBL225881 | 0.81 | CHRNB2 (0.53) | ESR1CHRNB2CHRNA4HPGDESR2 | |
| SCHEMBL225186 | 0.80 | ESR1 (0.37) | ESR1ESR2HPGDSRBP4PROKR1 | |
| SCHEMBL4689632 | 0.80 | CHRNB2 (0.41) | ESR1CHRNB2CHRNA4HPGDESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | claimed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| WO-2009155403-A2 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009065872-A2 | IMPROVED PROCESSES FOR THE SYNTHESIS OF VARENICLINE L-TARTRATE | MEDICHEM, S.A. (ES) | 2009-05-28 | — | — | WO | disclosed |
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | BUSCH FRANK R | 2008-11-06 | — | — | US | disclosed |
| EP-1866308-B1 | PREPARATION OF A HIGH PURITY SUBSTITUTED QUINOXALINE | PFIZER PROD INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1638971-B1 | PREPARATION OF SUBSTITUTED QUINOXALINES FROM THE DIANILINE WITH 2,3-DIHYDROXY-1,4-DIOXANE | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008060487-A2 | POLYMORPHS OF NICOTINIC INTERMEDIATES | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007110730-A2 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER PRODUCTS INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070224690-A1 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER INC | 2007-09-27 | — | — | US | disclosed |
| US-20070224690-A1 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER INC | 2007-09-27 | — | — | US | disclosed |
| US-20070185327-A1 | Preparation of substituted quinoxalines | PFIZER INC | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ESR1 4403/4885CHRNB4 101/4885CHRNA3 70/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | ESR1 4403/4885CHRNB4 101/4885CHRNA3 70/4885 |
| US-20070185327-A1 | Preparation of substituted quinoxalines | QDPR, DDT, NQO2 | ESR1 3427/4885CHRNB4 442/4885CHRNA3 116/4885 |
| US-20080275051-A1 | Preparation of High Purity Substituted Quinoxalines | QDPR, NQO2, NDUFA7 | ESR1 4825/4885CHRNB4 315/4885CHRNA3 611/4885 |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ESR1 4246/4885CHRNB4 43/4885CHRNA3 61/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | ESR1 4403/4885CHRNB4 101/4885CHRNA3 70/4885 |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ESR1 4403/4885CHRNB4 101/4885CHRNA3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.